US 100% tariff on generic drugs threatens Indian pharmaceutical exports
Conflict Comparison
Discrepancy in tariff percentage figures.
Open the listed sources to review each publisher’s original wording.
Note: AI has automatically cross-referenced facts from multiple sources. Please use your judgment considering source reliability.
Key Facts
- 01 — Who
Indian pharmaceutical industry
- 02 — Where
USA / India
- 03 — When
July 2026
This page is produced by collecting and structuring multiple public reports. Sections based only on reporting or testimony affect the displayed assessment, and the page is updated when new information is identified.
About this article
COMPAMIR Editorial Team
The COMPAMIR pipeline collects and structures publicly available reporting. The editorial team maintains the publication criteria and update policy.
Read our editorial policy- Revision v17/22/2026, 1:41:10 PM
The US is considering a 100% tariff on generic drug imports, which could significantly impact India's pharmaceutical industry. The US accounted for 37% of India's $26 billion pharma exports in 2025. Indian drugmakers face pressure to shift production or expand into higher-value medicines.